Stephen Feider is the Chief Financial Officer at BETA BIONICS INC., a pioneering medical technology company developing the iLet Bionic Pancreas to revolutionize diabetes management. With more than 25 years of experience in finance and operations within the healthcare and medtech industries, Feider oversees all financial aspects of the company, including strategic planning, fundraising, budgeting, and investor relations. He plays a pivotal role in guiding BETA BIONICS through its growth phase, ensuring fiscal discipline while supporting the commercialization of innovative insulin delivery systems. Feider's distinguished career includes serving as CFO at Companion Medical, where he led financial operations during its acquisition by Medtronic in 2019, and as Vice President of Finance at ev3 Inc., contributing to its successful sale to Covidien for $2.6 billion. Earlier roles at Boston Scientific and Guidant Corporation honed his expertise in global financial management, mergers and acquisitions, and scaling high-growth ventures. His achievements encompass securing over $200 million in venture funding across startups and optimizing financial structures to accelerate product development and market entry. At BETA BIONICS, Feider has been instrumental in raising significant capital rounds, including a landmark $100 million Series D financing, which has fueled FDA approvals and the nationwide launch of the iLet. His strategic foresight has positioned the company for sustained innovation, blending rigorous financial oversight with a commitment to transforming lives for the 40 million Americans living with diabetes.